title: Modeling of Optimal Targeted Therapies Using Drug-Loaded Magnetic Nanoparticles for Liver Cancer.
abstract: To enhance locoregional therapies for liver cancer treatment, we propose in this study a mathematical model to optimize the transcatheter arterial delivery of therapeutical agents. To maximize the effect of the treatment and minimize adverse effects on the patient, different mathematical models of the tumor growth are considered in this study to find the optimal number of the therapeutic drug-loaded magnetic nanoparticles to be administered. Three types of therapy models are considered, e.g., angiogenesis inhibition therapy, chemotherapy and radiotherapy. We use state-dependent Riccati equations (SDRE) as an optimal control methodology framework to the Hahnfeldt's tumor growth formulation. Based on this, design optimal rules are derived for each therapy to reduce the growth of a tumor through the administration of appropriate dose of antiangiogenic, radio- and chemo-therapeutic agents. Simulation results demonstrate the validity of the proposed optimal delivery approach, leading to reduced intervention time, low drug administration rates and optimal targeted delivery.
authors.forename: Lyes
authors.initials: L
authors.lastname: Mellal
authors.forename: David
authors.initials: D
authors.lastname: Folio
authors.forename: Karim
authors.initials: K
authors.lastname: Belharet
authors.forename: Antoine
authors.initials: A
authors.lastname: Ferreira
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003198:Computer Simulation; D004317:Doxorubicin / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D009682:Magnetic Resonance Spectroscopy / Q000627:therapeutic use*; D058185:Magnetite Nanoparticles / Q000627:therapeutic use*; D008954:Models, Biological; D009389:Neovascularization, Pathologic; D015019:Yttrium / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D058185:Magnetite Nanoparticles; D015019:Yttrium; D004317:Doxorubicin